Eplerenone, Aflibercept and Topical Nepafenac Serous Foveal Deta Chment in Central Serous Chorioretinopathy

Influence of Combined Eplerenone , Intravitreal Aflibercept and Topical Nepafenac Therapy on Serous Foveal Detachment in Central Serous Chorioretinopathy (CSCR)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05847049

Acronym

CSCR

Enrollment

Registered

2023-05-06

Start date

2023-02-28

Completion date

2023-04-06

Last updated

2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy

Brief summary

describing the influence of; combined Eplerenone, intravitreal Aflibercept, and topical Nepafenac; on serous foveal detachment in eyes with CSCR

Detailed description

Retrospective Review of records of eyes with Central serous chorioretinopathy (CSCR) that have been treated in the period between 2015 and 2021 After checking inclusion and exclusion criteria; we will enroll all cases that have been treated by the combination of eplerenone, intravitreal aflibercept and topical nepafenac. Investigators collected and recorded the following data: * Age * Gender * Systemic hypertension (present or not) * Smoking (Yes / No) * Best corrected visual acuity (BCVA) (baseline, final) * Central macular thickness (CMT) (baseline, final) * Serous detachment Height (SDH) (baseline, final) * Duration of Follow-up ( in months)

Interventions

OTHEREplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Eplerenone , Intravitreal Aflibercept and Topical nepafenac therapy

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 60 Years

Healthy volunteers

Inclusion criteria

* CSCR eyes treated by combination of Eplerenone, Aflibercept and Nepafenac.

Exclusion criteria

* • CSCR treated by other modalities * CSCR treated by just 1 or 2 components of :Eplerenone, Aflibercept and Nepafenac

Design outcomes

Primary

Measure	Time frame	Description
Change in central macular thickness (CMT ) in microns	(baseline, 6 months)	reduction in CMT after therapy
Change in serous detachment height (SDH) in microns	(baseline, 6 months)	reduction in SDH after therapy

Secondary

Measure	Time frame	Description
Change in BCVA	(baseline, 6 months)	number of lines of improvement in BCVA after therapy
Duration of Follow-up ( in months)	(baseline, 6 months)	Duration of Follow-up ( in months)
Complications (Eplerenone, Aflibercept, and nepafenac)	(baseline, 6 months)	present or absent

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026